You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Medidata's Glen de Vries argues at Stat News that drug companies should try to engage more deeply with their customers.
Principia will use Guardant's liquid biopsy assay to monitor the response of patients in a clinical trial of its FGFR inhibitor.
A blind woman in Texas has been treated with an optogenetic therapy, Technology Review reports.
Clinical trials are costly and lengthy, and precision medicine has introduced new challenges, but HBS is looking to award $50k to someone with a novel solution.
The firm found that for sub-chromosomal copy number variants, the test had a sensitivity of 97.7 percent and a specificity of 99.9 percent.
A scientist bemoans the lack of sharing of research results at academic medical centers.
The company hopes to begin marketing the so-called RealTime Oncology calculator, first in the US and then more broadly, starting in June.
In a JNCCN paper, the investigators discussed their efforts to comprehensively characterize a single patient's breast tumor and test potential treatments.
La Jolla, California-based startup Singlera has developed NIPT technology that evaluates both chromosomal aneuploidy and fetal DNA fraction.
A personalized medicine study has run into problems with poor tumor biopsy samples, Stat News reports.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.